Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia

International Journal of Urology : Official Journal of the Japanese Urological Association
Tomonori YamanishiKen-Ichiro Yoshida

Abstract

The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). Eviprostat was used as a control to study the efficacy of naftopidil. Forty-nine patients with BPH (mean age 67.9 +/- 7.8 years) were involved in the study. Patients were randomly assigned either to the naftopidil group, which was treated with the alpha-blocker naftopidil (50-75 mg daily, 36 patients), or the eviprostat group, which was treated with phytotherapy (six tablets of eviprostat daily, 13 patients). The mean total IPSS, the total storage and voiding symptom scores, and the quality of life score decreased significantly (P < 0.0001 for each variable) in the naftopidil group, but not in the eviprostat group. In the naftopidil group, analyses showed significant increases in average and maximum flow rate and bladder capacity at first desire to void (P < 0.001, P = 0.001 and P = 0.024, respectively), and significant decreases in the postvoid residual, the percent of residual and the Abrams-Griffiths number (P = 0.009, P = 0.008 and P = 0.042, respectively). However, in the eviprostat group, no significant changes were note...Continue Reading

References

Mar 1, 1991·Japanese Journal of Pharmacology·I MuramatsuS Kigoshi
Jan 1, 1994·Neurourology and Urodynamics·D M Gleason, M R Bottaccini
Jul 1, 1996·International Journal of Urology : Official Journal of the Japanese Urological Association·Y HommaY Ohashi
Sep 1, 1996·British Journal of Urology·A C Buck
Aug 28, 1998·The Journal of Urology·B J MalloyD A Schwinn
Oct 9, 2001·BJU International·H KakizakiT Koyanagi
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society

❮ Previous
Next ❯

Citations

Mar 25, 2008·Journal of Medicinal Food·Wei ZhangSam Z Sun
Jul 15, 2011·Therapeutics and Clinical Risk Management·Naoya Masumori
Nov 6, 2013·Current Medical Research and Opinion·Fabio CastiglioneFrancesco Montorsi
Dec 19, 2012·The Journal of Urology·Yoshihisa MatsukawaRyohei Hattori
Oct 20, 2009·The Journal of Urology·Yoshihisa MatsukawaRyohei Hattori
Feb 29, 2008·International Journal of Urology : Official Journal of the Japanese Urological Association·Debra A Schwinn, Claus G Roehrborn
Oct 12, 2018·The Cochrane Database of Systematic Reviews·Eu Chang HwangPhilipp Dahm
Oct 9, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Yukio HommaUNKNOWN Japanese Society of Neurogenic Bladder
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Pranav S GarimellaTimothy J Wilt
Feb 12, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Kazuhiro IshizakaKazunori Kihara
Aug 4, 2021·International Journal of Urology : Official Journal of the Japanese Urological Association·Hiroyuki Tsunemori, Mikio Sugimoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.